Dasatinib hæmmer aktivitet af BCR- ABL kinasen og kinaser, der tilhører SRC- kinasefamilien samt en række andre udvalgte onkogene kinaser, inklusive c- KIT, ephrinreceptor- kinaser og PDGFβ - receptorer.
Dasatinib inhibits the activity of the BCR-ABL kinase and SRC family kinases along with a number of other selected oncogenic kinases including c-KIT, ephrin (EPH) receptor kinases, and PDGFβ receptor.